Literature DB >> 9692563

Follow-up of more than 10 years after endoscopic sphincterotomy for choledocholithiasis in young patients.

M Sugiyama1, Y Atomi.   

Abstract

BACKGROUND: With the advent of laparoscopic cholecystectomy, the indications for endoscopic sphincterotomy (ES) have been extended to young patients with choledocholithiasis. However, the long-term results of ES are largely unknown.
METHODS: Between 1977 and 1986, 115 patients aged 60 years or less underwent ES for choledocholithiasis. Stone classification, and early and long-term outcomes of ES were analysed retrospectively.
RESULTS: Early complications occurred in nine patients (7.8 per cent), but there were no deaths. ES and stone clearance were successful in 110 patients. Long-term information was available in 103 of the 110 patients, with a mean overall follow-up duration of 14-2 (range 10.4-19.3) years. Ten patients (9.7 per cent) developed late complications, including stone recurrence and/or cholangitis (nine patients) and acute cholecystitis (one of 23 patients with the gallbladder in situ). The choledochal complication rate was somewhat higher in patients with calcium bilirubinate stones at ES (seven of 65 patients) than in those with cholesterol stones (two of 38 patients). Choledochal complications were manageable endoscopically.
CONCLUSION: Approximately 10 per cent of patients develop late complications. However, endoscopic retreatment is safe and effective. ES is a reasonable method for treating choledocholithiasis, even in young patients.

Entities:  

Mesh:

Year:  1998        PMID: 9692563     DOI: 10.1046/j.1365-2168.1998.00750.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  24 in total

1.  Gallstones.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-04

Review 2.  Recurrent bile duct stones after endoscopic sphincterotomy.

Authors:  S Sultan; J Baillie
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

3.  Endoscopic retreatment of recurrent choledocholithiasis after sphincterotomy.

Authors:  M Sugiyama; Y Suzuki; N Abe; T Masaki; T Mori; Y Atomi
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

4.  [Therapeutic splitting as standard treatment for cholelithiasis].

Authors:  U T Hopt; U Adam
Journal:  Chirurg       Date:  2006-04       Impact factor: 0.955

5.  Stone clearance and risk factors for failure in laparoscopic transcystic exploration of the common bile duct.

Authors:  Cecilia Strömberg; Magnus Nilsson; Carl-Eric Leijonmarck
Journal:  Surg Endosc       Date:  2008-05       Impact factor: 4.584

6.  Laparoscopic Transcystic Common Bile Duct Exploration in the Emergency Is as Effective and Safe as in Elective Setting.

Authors:  Matias E Czerwonko; Juan Pekolj; Pedro Uad; Oscar Mazza; Rodrigo Sanchez-Claria; Guillermo Arbues; Eduardo de Santibañes; Martín de Santibañes; Martín Palavecino
Journal:  J Gastrointest Surg       Date:  2018-11-12       Impact factor: 3.452

7.  The ballooning time in endoscopic papillary balloon dilation for the treatment of bile duct stones.

Authors:  Byoung Wook Bang; Seok Jeong; Don Haeng Lee; Jung Il Lee; Jin-Woo Lee; Kye Sook Kwon; Hyung Gil Kim; Yong Woon Shin; Young Soo Kim
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 2.884

8.  Effect of medical or surgical admission on outcome of patients with gallstone pancreatitis and common bile duct stones.

Authors:  Jennifer LaFemina; Suzanne M Sokal; Yuchiao Chang; Deborah McGrath; David L Berger
Journal:  J Gastrointest Surg       Date:  2008-07-12       Impact factor: 3.452

9.  Long-term biliary endoscopic sphincterotomy restenosis: incidence, endoscopic management, and complications of retreatment.

Authors:  Farshad Elmi; William B Silverman
Journal:  Dig Dis Sci       Date:  2010-07       Impact factor: 3.199

10.  Comparative quality of life study between endoscopic sphincterotomy and surgical choledochotomy.

Authors:  Feng Liu; Xue Bai; Guang-Feng Duan; Wen-Hua Tian; Zhao-Shen Li; Bin Song
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.